Harvard Medical School
Johns Hopkins Medicine
Department of Defense
University of Missouri
Rutgers RWJMS
Mount Sinai
Wake Forest University
Johns Hopkins University · Peer-reviewed · PLoS ONE

Johns Hopkins: Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration

Read More

Press Releases

Peer Reviews

Johns Hopkins University · Peer-reviewed · PLoS ONE

Johns Hopkins: Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration

A preclinical Johns Hopkins study, co-authored by Kurve CEO Marc Giroux, found that intranasal delivery reached the brain far more selectively than injection, in rodents and a non-human primate.

Read peer review

Interested in ViaNase™?

ViaNase™ is available through Kurve’s clinical studies and FDA expanded access (compassionate use). Tell us who you are and we’ll guide you to the right route.

Interested in ViaNase